Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Follow us on Google+Follow us on TwitterFind us on LinkedInFind Us on FacebookSubscribe to our RSS FeedsSubscribe to our YouTube ChannelFind us on RebelMouse

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for December 13, 2012 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   



Dr. R.Deshaies Cal Tech, to Speak at Ubiquitin Research Conference Feb 25-26, 2013 in Las Vegas, NV

Dr. R.Deshaies Cal Tech, to Speak at Ubiquitin Research Conference Feb 25-26, 2013 in Las Vegas, NV
 
x-small text small text medium text large text

    MONROVIA, CA, December 13, 2012 /24-7PressRelease/ -- Dr. Deshaies is Professor and Executive Officer of Biology at the California Institute of Technology and an Investigator at the Howard Hughes Medical Institute. His career has focused on investigating the cellular machinery that mediates protein degradation by the Ubiquitin-Proteasome System (UPS), and how this machinery regulates cell division. Dr. Deshaies is a leading figure in the Ubiquitin field, has published over 100 papers and is an inventor on nine U.S. patents, many related to his work on the UPS. For information on his work, visit http://www.its.caltech.edu/~rjdlab/. Dr. Deshaies has received numerous awards and scholarships, including the Markey and Searle Scholar Awards and Burroughs-Wellcome and Beckman New Investigator Award; in 1999 he was selected as Young Investigator of the Year by the American Society for Cell Biology and in 2011 was elected to the American Academy of Arts and Sciences. In addition to being a co-founder of Cleave Biosciences, Dr. Deshaies was the academic co-founder of Proteolix, which was sold in October 2009 to Onyx in a deal valued at up to $851 million.

The 3rd Ubiquitin Research and Drug Discovery Conference will bring together a 50-50 mix of academic and industry experts from leading affiliations (such as Elan, Millenium, Genentech, Celgene, Novartis, Onyx, Amgen, Cal-Tech, Emory University, Harvard, University of Washington, UCLA, etc.) to cover many current and relevant aspects of the Ubiquitin Proteasome Sturcture, Ligases, Sumo and more.

This conference is also part of the 2nd Novel Cancer Therapeutic Summit, which consists of this track and two others:
4th Cancer Targets and Therapeutics
2nd Oncology Partnering and Deal Making

For more information, please visit http://www.gtcbio.com

ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com



---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Read more Press Releases from Rania Hafez:

Contact Information:
Rania Hafez
GTCbio

Monrovia, CA
USA
Voice: 626-256-6405
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.